Cutaneous atrophy arising irom prolonged use of potent topical corticosteroids has long been a concern. Thus, it would be advantageous to lind an agent which protects against atrophy produced by corticosteroids but at the same time does not impair their anti-intlammatory effects. Recent work shows that topical all-fruMs retinoic acid (tretinoin) prevents skin atrophy in mice treated with topical corticosleroids. but such studies have nol been performed in humans. We performed an 8-week clinical, histoiogical and biochemical study to test the ability of tretinoin to enhance efficacy and inhibit atrophogenicity of topical corticosteroids. when used in the treatment of psoriasis. In each of 20 psoriasis patients, one plaque, and its perilesional skin, was trealed once daily with betamethasone dipropionate and tretinoin ()'1%. and one plaque, and its perilesional skin, treated with once daily betamethasone dipropionate and tretinoin vehicle. There was no difference in the speed or degree of improvement in plaques treated with either the topical corticosteroid/tretinoin combination or with corticosteroid alone. Ijght microscopy revealed a 19% reducti(Hi in epidermal thickness, in corticosteroid-treated perilesional skin, as compared with a slight (l'Xil increase in corticosteroid/ tretinoin-treated perilesional areas (P = {){)fi7|. Western blot analysis showed a 55% reduction in procollagen I aminopropeptide in periiesional skin treated with corticosteroid alone, as compared with a 45% reduction in corticosteroid/tretinoin-treated perilesionai skin. These data indicate that the addition of tretinoin does not impair the efficacy of a topical corticosteroid, in the treatment of psoriasis, and partially ameliorates epidermal atrophy produced hy the topical corticosteroid.
Topical corticosteroids are helpful for the treatment of inflammatory dermatoses but their prolonged use may be associated with cutaneous atrophy. Studies in mice have demonstrated that concurrently applied all-tra?is retinoic acid (trctinoini may prevent cutaneous atrophy produced by topical corticosteroids.^ Lesnik ct ai~ have demonstrated that tretinoin will prevent corticosteroidinduced skin atrophy in hairless mice, hut without impairment of corticosteroid anti-inflammatory properties. Results of another study^ are also compatible with tbis observation, as tretinoin does not alter the vasoconstrictive properties of topical corticosteroids in normal human skin. Atopic dermatitis also responds well to a combination of tretinoin and a mid-potency topical steroid, without any increased irritation."T hus far. no controlled study in humans bas assessed the ability of tretinoin to. either, protect against corticosteroid-induced cutaneous atrophy or enhance the anti-inflammatory properties of corticosteroids. To address these questitins. we investigated the ability of topical tretinoin to prevent atrophy of surrounding psoriatic skin during treatment with a topical corticosleroid. and to enhance the efficacy of a midpotency topical corticosteroid. during the treatment of psoriatic plaques.
Methods

Ptitii'itts
Twenty, healthy psoriatic patients (17 men. three women; age range 25-70. mean age 46 years), each with al least three stable psoriatic plaques of similar severity and size, were entered into an 8-week, doubleblind vehicle-controlled study. No topical or oral treatments, including ultraviolet radiation, other than bland emollients, were allowed within the 4 weeks preeeding (he study, or during the study itself. Pregnant and nursing women were excluded. All patients gtive written informed consent, and the protocol was approved by ihe institutional review board of the University of Michigan Medical Center. Three, clinically similar, psoriatic plaques were chosen, on each patient. One plaque remained unlreated and served as a control. The other two plaques were treated each morning with a mid-potency topical corticosteroid. i)-05% betamethasone dipropionate cream (BD: U-05% Diprosone. Schering Corporalion. Kenilworth, New Jersey. U.S.A.) and were randomized to evening treatment with either {)-l% tretinoin eream (Retin-A"^'. Ortho Pharmaceutical Corporation. Raritan. New Jersey. U.S.A.) or colourmatched vehicle cream (Ortho). Each study plaque was a minimum of 5 cm in diameter, to ensure suilicient biopsy area, and all treatments were applied to the active plaque and to 5 em of uninvolved perilesional skin. No study drugs were applied on the evening before, or on the morning of. scheduled clinic visits. All patients recei\'ed a mild emollient to be used, when needed, for skin irritation or dryness. As all dispensed tubes were identical in appearance, both investigators and patients were unaware of the treatment group to which each plaque was assigned. The sample sizes were chosen to provide a statistical power of approximately ()-80 to detect a mean difference of 1 5 /im in epidermal thickness, at the end of therapy, between BD/tretinoin and Bl)/vehicle at a type I error rate of 0-()5, for a twosided paired comparison.
Clinical evahiatfous
Clinieal evaluations were performed at baseline, and at weeks 1. 2. 4. 6 and 8 of therapy. One investigator (AJM) evaluated all patients at ali visits. At the baseline visit only, an overall evaluation of the severity of psoriasis for all three plaques was performed, using a li\'e-p{)int scale where 1 indicates no psoriasis: 2. mild: 5. moderate: 4. severe and 5, very severe. At both baseline and follow-up visits, scaling, erythema and plaque elevation were each assessed for eaeh plaque on a nine-point. 0-8 scale. At follow-up visits only, a global evaluation, compared with baseline, for all plaques, was performed on a seven-point scale with 1 indicating markedly worse: 2. worse: 3, slightly worse: 4, no change: 5. slightly improved: fi, improved: and 7. markedly improved. Also, skin atrophy of all three plaques, and their corresponding perilesional skin.
was evaluated on a six-point scale with 1 indicating none: 2, trace: 3. mild: 4. moderate: S. marked: and 6, severe.
Side-effects
At each visit, cutaneous side-effects at all treatment sites, and their corresponding perilesional skin, were evaluated by measuring erythema, peeling, itching, burning/stinging, depression, striae, wrinkling and telangiectasia. using the aforementioned six-point scale. Eor cutaneous effects, only increases of two or more units, over baseline, at two or more visits, were evaluated statistically.
Lifllil microscopii
Two. 4 mm punch biopsies, one from the plaque and one from perilesional skin of each treated plaque, were obtained at baseline and after 8 weeks of treatment. The biopsies were immediately bisected, and one-half placed in 10% neutral-buffered formalin, embedded in paraffin, sectioned, and stained with haematoxylin and eosin. The other half of the specimen was either placed in optimal cutting temperature medium (OCT. Miles Laboratories. Elkhart. Indiana. U.S.A.) and snap frozen in liquid nitrogen, or directly frozen in liquid nitrogen, and stored at -70'^C until processed for Western blot analysis. The investigator who analysed the histological specimens (L)I"| was not aware of either the patient's treatment or the timing of the biopsy. Stratum corneum compaction, granular cell layer thickness, spongiosis and dermal inflammation were assessed using a semiquantitative scale ranging from 0 to 4. where 0 was no evidence of parameter, and 4 was maximum expression. Epidermal thickness in /im was measured from the top of the gratiular layer to the epidermal basement membrane, in five inter rete-ridge spaces per specimen.
Western hlot analysis
Procollagen was extracted from skin biopsies, as described,''*' and supernatants prepared for Western blot analysis of type I procollagen aminopropeptide (pNcoI I). Incubations were performed with affinity purified anti-pNcol I polyclonal antibody (a generous gift of Drs |. and L.Ristelli, University of Oulu, Finland) overnight at 4'^C, and pNcol I identified by comigration with authentic standards (a generous gift of Prof. M.Lapiere, University of Liege. Belgium). Radioactivity in the bands was measured by Phosphorimager (Molecular Dynamics), and results expressed as counts per minute/unit protein.
Statistical analysis
Comparisons of the change from baseline in clinical and histological parameters, between sites treated with corticosteroid alone, vs. those treated with corticosteroid plus tretinoin. were made with the paired t-test. The nonparametric Wilcoxon signed-rank test was used to compare changes in pNcol I levels, as determined by Western blot analysis due to the non-normal distribution of the data. All P values were two-tailed. Summary statistics are expressed as means ± standard error of the mean (SEM). The data were analysed with the use of the Michigan Interactive Data Analysis System (MIDAS), a statistical software package developed by the Centre for Statistical Consultant and Research, at the University of Michigan.
Results
Seventeen of 20 patients completed the 8-week study, although only 16 of them had the final 8-week biopsy performed. Two patients dropped out. one after week 4, and one after week 6. because of personal responsibilities. One patient discontinued the study at week 1, secondary to a protocol violation of applying topical study creams to the control site. One patient refused biopsy upon completion of the study. Therefore, clinical data are presented for 1 7 patients and histological data for 16 patients. 
Clinical findings
Assessment of the clinical global response revealed that all patients had at least slight improvement in their psoriasis, at both treated sites, after 8 weeks of treatment. Sites treated with BD/tretinoin showed a marked improvement in nine (S3%) patients, an improvement in four (24%) and H slight improvement in four. Similarly, sites treated with BD/vehicle demonstrated a marked improvement in nine (53%) patients, an improvement in three (18%). and a slight improvement in five (29%). Control, untreated sites, showed a slight improvement in five (29%) patients, no change in 10 (59%). and a worsening in two (12%). The speed of improvement was no different between the two treatment sites. Thus, the two treatments were equally efficacious and the addition of tretinoin conferred no added advantage in efficacy to BD for psoriasis treatment {Fig. 1). Furthermore, at completion of the stndy (week 8), no clinical atrophy was noted in any perilesional area.
Side-effects
Cutaneous reactions were characterized principally by erythema and scaling. Erythema and/or scaling of at least moderate severity occurred in six of 19 (32%) patients, in the tretinoin-treated plaques, and in one of 19 (5%) patients, in the vehicle-treated plaques, during the study.
Histological findings
In perilesional skin treated with BD/vehicle, the epi- 
y^esiern blot analysis
Owing to three spccimetis not beitig snap frozen, only 1 3 biopsy samples were available for analysis by Western blotting. In perilesional skin treated for 8 weeks with BD/vehicle, there was a 55'^ reduction in pNcoII.from 1211 ± 365 at baseline to 458 ± 161 at 8 weeks. In BD/tretinoin treated skin, there was a lesser. 45%, reduction in pNcoll, from 1178 ± 3 38 at baseline to 650 ± 208 at 8 weeks (P = 0 07).
Discussion
The combination of topical eortieosteroids and tretinoin for the treatment of psoriasis is not a new idea. As early as 1973. it was demonstrated that fluorinated eortieosteroids combined with tretinoin-cleared psoriatic plaques, perhaps with enhanced clinical therapeutic effect.'' Kaidbey cl al.^ showed that combined therapy with ()-l% tretinoin and potent topical corticosteroid was efficacious in psoriasis, but the issue of skin atrophy was not addressed. We observed no difference in the speed of resolution nor in the degree ofimprovement of psoriatic plaques treated with corticosteroid and vehicle, as compared with plaques treated with corticosteroid and tretinoin for 8 weeks. We did not observe that the addition of 0 1% tretinoin increased corticosteroid efficacy, but this may be because efficacy ofthe corticosteroid that we used (BD) may already be very close to. or at the peak of. the dose-response curve. Thus, it still remaitis that efficacy of a mild potency topical corticosteroid could be enhanced by the addition of tretinoin.
Although we could not demonstrate clinical atrophy in skin treated with corticosteroid alone, there was both histological and biochemical evidence that atropby had occurred. Furthermore, the addition of tretinoin to the corticosteroid protected, to some extent, against epidermal atrophy. The \9% decrease in epidermal thickness during corticosteroid treatment was similar to that observed hy Lesnik ct al.~ in the mouse ear model, where potent topical eortieosteroids thinned the epidermis to two cell layers. In our study, the significant compaction of stratum corneuin and thickening of granular layer, with the addition of tretinoin, are markers of retinoid activity and per se may not be evidence of a protective effect of tretinoin.
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In addition, we investigated collagen precursor content in the dermal matrix. It is known from studies in rats,*^ that triamcinolone diiicetate decreases synthesis of type I procollagen. in addition to other coilagens. Furthermore, it has recently been demonstrated that topical tretinoin can restore synthesis of collagen I in photoaged human skin,^" and collagen III in photoaged mouse skin. pNcol I was reduced to a lesser, although non-significant, extent in the corticosteroid/tretinointreated sites as compared with corticosteroid alone, implying that topical retinoids may partially abrogate corticosteroid-induced decreases in collagen synthesis. Further study is required to prove that it is indeed the synthesis, and not rale of breakdown, of collagen that is affected by topical tretinoin.
